These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

714 related items for PubMed ID: 18974645

  • 1. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina.
    Fernández Canigia L, Kaufman S, Lanata L, Vay C, Giovanakis M, Bantar C, Argentinean Tigecycline Surveillance Group.
    Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS, Jones RN, Dowzicky MJ, Fritsche TR.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [Abstract] [Full Text] [Related]

  • 3. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ.
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [Abstract] [Full Text] [Related]

  • 4. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [Abstract] [Full Text] [Related]

  • 5. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
    Bouchillon SK, Iredell JR, Barkham T, Lee K, Dowzicky MJ.
    Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
    [Abstract] [Full Text] [Related]

  • 6. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
    Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST) Group.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [Abstract] [Full Text] [Related]

  • 8. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.
    Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):181-6. PubMed ID: 16105562
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
    Garrison MW, Mutters R, Dowzicky MJ.
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints.
    Papaparaskevas J, Tzouvelekis LS, Tsakris A, Pittaras TE, Legakis NJ, Hellenic Tigecycline Study Group.
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):187-94. PubMed ID: 19836184
    [Abstract] [Full Text] [Related]

  • 11. Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery.
    Tubau F, Liñares J, Rodríguez MD, Cercenado E, Aldea MJ, González-Romo F, Torroba L, Berdonces P, Plazas J, Aguilar L, Delgado A, García-Escribano N, Study Group.
    Diagn Microbiol Infect Dis; 2010 Mar; 66(3):308-13. PubMed ID: 20022193
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial activity of tigecycline against bacterial isolates from intensive care units in a teaching hospital in Central Saudi Arabia.
    Somily AM, Al-Khattaf AS, Kambal AM.
    Saudi Med J; 2010 Jan; 31(1):18-24. PubMed ID: 20062893
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
    Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST Program) Group.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567
    [Abstract] [Full Text] [Related]

  • 14. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.
    Bouchillon SK, Hoban DJ, Johnson BM, Stevens TM, Dowzicky MJ, Wu DH, Bradford PA.
    Diagn Microbiol Infect Dis; 2005 Apr; 51(4):291-5. PubMed ID: 15808321
    [Abstract] [Full Text] [Related]

  • 15. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ, Park CH.
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [Abstract] [Full Text] [Related]

  • 16. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
    Roveta S, Marchese A, Debbia EA.
    Chemotherapy; 2008 Nov; 54(1):43-9. PubMed ID: 18073470
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS, Whitelaw A, Dowzicky MJ.
    Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
    [Abstract] [Full Text] [Related]

  • 18. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE, Rybak MJ.
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [Abstract] [Full Text] [Related]

  • 19. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
    Seifert H, Dowzicky MJ.
    Chemotherapy; 2009 Aug; 55(4):241-52. PubMed ID: 19468222
    [Abstract] [Full Text] [Related]

  • 20. In vitro activity of tigecycline against resistant micro-organisms isolated from burn patients.
    Timurkaynak F, Arslan H, Azap OK, Senger SS, Başaran O, Karaman SO, Haberal M.
    Burns; 2008 Nov; 34(7):1033-6. PubMed ID: 18539397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.